Atala Financial Inc Purchases Shares of 465 IQVIA Holdings Inc. (NYSE:IQV)

Atala Financial Inc purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, Holdings Channel.com reports. The firm purchased 465 shares of the medical research company’s stock, valued at approximately $91,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at about $1,616,000. Simplify Asset Management Inc. raised its stake in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares during the period. Nordea Investment Management AB raised its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA in the 4th quarter valued at about $941,000. Finally, Fifth Third Bancorp increased its position in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Barclays lowered their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Morgan Stanley lifted their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Trading Up 2.2 %

Shares of NYSE:IQV opened at $185.40 on Friday. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $256.34. The stock has a market cap of $32.69 billion, a PE ratio of 24.72, a P/E/G ratio of 1.99 and a beta of 1.50. The business has a 50 day moving average of $196.63 and a 200-day moving average of $210.95. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.